T-cell lymphoma market to more than double to $5.16B by 2035, driven by immunotherapy advances.

The global T-cell lymphoma market, valued at $2.25 billion in 2025, is projected to reach $5.16 billion by 2035, growing at a CAGR of 8.66%. This growth is fueled by rising disease prevalence, especially among older adults, and innovations in targeted therapies and immunotherapies like CAR-T cell therapy. The U.S. leads the market due to strong biotech innovation and rapid drug approvals, while Asia Pacific is the fastest-growing region. Major pharmaceutical companies are actively developing new treatments, with immunotherapy emerging as the fastest-growing segment, offering better survival rates and fewer side effects compared to traditional chemotherapy.